Epicutis’ Hydrobiome Serum targets post-procedure barrier repair, while CEO Max Stock explains physician-guided care and biotech’s microbiome future.
Maxwell Stock
Advertisement
Maxwell Stock is the founder and CEO of Signum Biosciences and creator of Epicutis Skincare.
Articles by Maxwell Stock
Microbiome-first biotech in dermatology is shifting from harsh acne treatments to balance-focused solutions, using anti-inflammatory compounds that support healthier skin ecosystems.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 1b Trial of FB102 Demonstrates Significant Facial Repigmentation and Sustained Vitiligo Response
2
First Patient Dosed in Phase 2 Trial of Topical Pan-JAK Inhibitor LNK01004 for Vitiligo
3
FDA Accepts sNDA for Roflumilast Cream 0.05% in Infants With Atopic Dermatitis Down to 3 Months
4
Guselkumab APEX Trial Supports New Joint Damage Label
5